4th Quarter - Amendment

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$1,840,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 22, 2018 $1,840,000 Replaced
4th Quarter - Amendment Jan 22, 2018 $1,840,000 Replaced
4th Quarter - Amendment Sep 17, 2020 $1,840,000 Replaced
4th Quarter - Amendment (this page) Sep 17, 2020 $1,840,000 Yes

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

HR1 tax bill, issues relating to the tax treatment of nonprofits, including charitable deductions, elimination of the individual fee for the Affordable Care Act, deduction of health care costs by individual tax payers, and availability of the Orphan Drug Tax Credit. Also expanding the availability of the charitable deduction for non-itemizers respecting H.R. 3988 and S. 2123. Also, creating parity in taxation of tobacco products respecting S. 1837

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
OKEYSHA BROOKS-COLEY —
GREGG HAIFLEY —
RACHEL MARCUS —
CAROLINE POWERS —
RICHARD WOODRUFF —

Contacted: Environmental Protection Agency (EPA); Labor, Dept of (DOL); White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Bills named: H.R. 1 (115th), H.R. 3988 (115th), S. 2123 (115th), S. 1837 (115th)

Health Issues HCR

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act. Preservation of the Prevention and Public Health Fund and reauthorization of the CHIP program and FQHCs respecting H.R. 3922. Issues relating to anti-cancer medication cost-sharing parity respecting H.R. 1409. Issues regarding a national family caregiving strategy respecting S. 1719 and H.R. 1028. Issues regarding access to medicines respecting S.204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, as well as H.R.878, the Right to Try Act of 2017. Issues regarding lymphedema treatment respecting The Lymphedema Treatment Act, H.R. 930 and S. 497. Issues regarding access to care respecting the Bi-partisan Health Care Stabilization Act (Alexander-Murray) and S 1835, The Lower Premiums through Reinsurance Act.

Contacted: Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); State, Dept of (DOS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Environmental Protection Agency (EPA); U.S. Agency for International Development (USAID); Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; White House Office; Labor, Dept of (DOL)

Bills named: S. 1719 (115th), H.R. 930 (115th), H.R. 878 (115th), S. 292 (115th), H.R. 1676 (115th), H.R. 1231 (115th), S. 497 (115th), H.R. 772 (115th), H.R. 1409 (115th), H.R. 1028 (115th), S. 693 (115th), H.R. 3922 (115th), S. 456 (115th), S. 204 (115th), S. 261 (115th), H.R. 820 (115th)

Medicare/Medicaid MMM

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the Better Care Reconciliation Act, and the Graham-Cassidy-Heller, Johnson repeal. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, 479; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; State, Dept of (DOS); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); White House Office; Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); Labor, Dept of (DOL); Food & Drug Administration (FDA)

Bills named: S. 479 (115th), H.R. 1017 (115th), H.R. 1628 (115th)

Budget/Appropriations BUD

Federal budget and appropriations for cancer research and programs, including: FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act; issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act; issues related to medical isotopes with respect to the Energy and Water Development Appropriations Act; and issues relating to veterans cancer screenings with respect to the Military Construction and Veterans Affairs Appropriations Act.

Contacted: Food & Drug Administration (FDA); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); White House Office; U.S. Trade Representative (USTR); Labor, Dept of (DOL)

Tobacco TOB

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smoke-free environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations, and H.R. 2194 Cigarette Smoking Reduction and Electronic Vapor Alternatives Act of 2017. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY18 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation. Issues related to making Veterans Health Administration facilities smoke-free respecting H.R. 1662, H.R. 1848, and S. 2119. Issues regarding parity in taxation of tobacco products respecting S. 1837. Issues regarding raising the age for legal sale of tobacco products respecting S. 2100 and H.R, 4273.

Contacted: Health & Human Services, Dept of (HHS); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); White House Office; Labor, Dept of (DOL); Natl Institutes of Health (NIH); SENATE; U.S. Trade Representative (USTR); Centers For Disease Control & Prevention (CDC); State, Dept of (DOS)

Bills named: H.R. 2194 (115th), S. 294 (115th), S. 1837 (115th), H.R. 1136 (115th), S. 2119 (115th), H.R. 564 (115th), S. 2100 (115th), H.R. 1848 (115th), H.R. 1662 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.